DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom ...
Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is ...
Add Yahoo as a preferred source to see more of our stories on Google. Eligible patients had received between one and four previous lines of chemotherapy. Credit: Thomas Andreas via Shutterstock.
WILMINGTON, Del., February 03, 2026--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY ® (datopotamab deruxtecan-dlnk) has been accepted ...
(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab deruxtecan) has been approved in the United States for ...
Datroway received FDA accelerated approval for EGFR-mutated NSCLC after progression on EGFR-targeted therapy and platinum-based chemotherapy. Clinical trials showed a 45% overall response rate and a ...
Based on TROPION-Lung05 results and supported by data from TROPION-Lung01 First and only TROP2-directed therapy approved in the US for the treatment of lung cancer WILMINGTON, Del.--(BUSINESS WIRE)-- ...
Positive high-level results from the TROPION-Breast02 phase III trial showed Datroway (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the ...
Add Yahoo as a preferred source to see more of our stories on Google. AstraZeneca and Daiichi Sankyo's ADC AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab ...
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY®(datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment ...
DATROWAY ® has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR- mutated non-small cell lung cancer who have received prior EGFR- directed therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results